MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

Search

Grifols SA

Fechado

SetorFinanças

8.408 0.17

Visão Geral

Variação de preço das ações

24h

Atual

Mín

8.344

Máximo

8.704

Indicadores-chave

By Trading Economics

Rendimento

17M

69M

Vendas

183M

2B

P/E

Médio do Setor

45.229

22.015

EPS

0.101

Margem de lucro

3.491

Funcionários

23,833

EBITDA

57M

482M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+72.24% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

3.3B

6.8B

Abertura anterior

8.24

Fecho anterior

8.408

Sentimento de Notícias

By Acuity

65%

35%

484 / 542 Ranking em Finance

Pontuação Técnica

By Trading Central

Confiança

Neutral Evidence

Grifols SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de abr. de 2025, 17:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Grifols in 'Very Preliminary Talks' With Brookfield Over Renewed Takeover Bid -- 2nd Update

2 de abr. de 2025, 13:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Grifols, Brookfield Deny Takeover Talks After Report of Renewed Interest -- Update

2 de abr. de 2025, 10:13 UTC

Aquisições, Fusões, Aquisições de Empresas

Grifols Board Denies Media Reports Over Talks With Brookfield for Another Takeover Bid

8 de jul. de 2024, 10:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Trending: Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker

8 de jul. de 2024, 09:13 UTC

Aquisições, Fusões, Aquisições de Empresas

Grifols Faces Delisting Bid From Founding Family and Brookfield

2 de abr. de 2025, 09:27 UTC

Ações em Alta

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Comparação entre Pares

Variação de preço

Grifols SA Previsão

Preço-alvo

By TipRanks

72.24% parte superior

Previsão para 12 meses

Média 14.02 EUR  72.24%

Máximo 19.05 EUR

Mínimo 11 EUR

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Grifols SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

3 ratings

2

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

8.152 / 8.574Suporte e Resistência

Curto Prazo

Neutral Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

484 / 542 Ranking em Finanças

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.